Figura suplementaria S1 de Evaluación de Copanlisib en combinación con Eribulin en modelos de xenoinjertos derivados de pacientes con cáncer de mama triple negativo

Guo et al. (mié,) estudiaron esta cuestión.

www.synapsesocial.com/papers/68e660cfb6db6435875eed1e — DOI: https://doi.org/10.1158/2767-9764.25976516

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Figure S1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models· 2024
2. Supplementary Figure S3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models· 2024
3. Supplementary Figure S3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models· 2024
4. Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models· 2024
5. Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models· 2024